{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:14:09Z","timestamp":1787019249526,"version":"build-2736575974"},"reference-count":95,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Technol Cancer Res Treat"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:p>Traditionally, radiotherapy in metastatic renal cell carcinoma (RCC) was applied for the palliation of symptoms and the control of critical sites such as bone lesions and brain metastases. However, technological advances in radiotherapy (RT) planning and delivery made it possible to precisely deliver high dose radiotherapy at a confined target volume. One such approach is stereotactic body radiotherapy (SBRT). In patients presenting with limited metastatic burden, known as oligometastatic RCC (omRCC), SBRT can be of interest to maintain local control, in order to defer the onset of either a first or a subsequent line of systemic treatment. In this narrative review, we summarize the prospective and retrospective evidence on SBRT as a treatment option for omRCC, and give insight into the future perspectives.<\/jats:p>","DOI":"10.1177\/15330338251357344","type":"journal-article","created":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T07:57:14Z","timestamp":1752739034000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Stereotactic Body Radiotherapy for Extracranial Oligometastatic Renal Cell Carcinoma: State of the Art and Future Perspectives"],"prefix":"10.1177","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-6827-1992","authenticated-orcid":false,"given":"Sander","family":"Vandaele","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, University Hospitals Leuven, Leuven, Belgium"},{"name":"Catholic University of Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6763-6586","authenticated-orcid":false,"given":"Maarten","family":"Albersen","sequence":"additional","affiliation":[{"name":"Catholic University of Leuven, Leuven, Belgium"},{"name":"Department of Urology, University Hospitals Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7427-9102","authenticated-orcid":false,"given":"Benoit","family":"Beuselinck","sequence":"additional","affiliation":[{"name":"Catholic University of Leuven, Leuven, Belgium"},{"name":"Department of Medical Oncology, University Hospitals Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7453-0229","authenticated-orcid":false,"given":"Karolien","family":"Goffin","sequence":"additional","affiliation":[{"name":"Catholic University of Leuven, Leuven, Belgium"},{"name":"Department of Nuclear Medicine, University Hospitals Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0800-3279","authenticated-orcid":false,"given":"Vincent","family":"Vandecaveye","sequence":"additional","affiliation":[{"name":"Catholic University of Leuven, Leuven, Belgium"},{"name":"Department of Radiology, University Hospitals Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0697-3116","authenticated-orcid":false,"given":"Henri","family":"Vandermeulen","sequence":"additional","affiliation":[{"name":"Catholic University of Leuven, Leuven, Belgium"},{"name":"Department of Radiology, University Hospitals Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9661-1436","authenticated-orcid":false,"given":"Charlien","family":"Berghen","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University Hospitals Leuven, Leuven, Belgium"},{"name":"Catholic University of Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,7,17]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.07.005"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2018.08.036"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-016-1773-y"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2007.12.001"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2011.05.012"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25836"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15061804"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.wneu.2017.10.011"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1080\/0284186X.2021.1989720"},{"key":"e_1_3_2_12_2","doi-asserted-by":"crossref","unstructured":"Quhal F Mori K Bruchbacher A Resch I Mostafaei H. First-line immunotherapy-based combinations for metastatic renal cell carcinoma: A systematic review and network. 2021:4.","DOI":"10.1016\/j.euo.2021.03.001"},{"key":"e_1_3_2_13_2","doi-asserted-by":"crossref","unstructured":"Schoenhals JE Mohamad O Christie A et al. Stereotactic ablative radiation therapy for oligoprogressive renal cell carcinoma. 2021:1-10.","DOI":"10.1016\/j.adro.2021.100692"},{"key":"e_1_3_2_14_2","first-page":"283","article-title":"Nivolumab in combination with stereotactic body radiotherapy in pretreated patients with metastatic renal cell carcinoma. Results of the phase II NIVES study","volume":"1","author":"Masini C","year":"2021","unstructured":"Masini C, Iotti C, Giorgi UDe, et al. Nivolumab in combination with stereotactic body radiotherapy in pretreated patients with metastatic renal cell carcinoma. Results of the phase II NIVES study. Eur Urol. 2021;1:283-284.","journal-title":"Eur Urol."},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1803675"},{"key":"e_1_3_2_16_2","article-title":"First-line systemic treatment strategies for unresectable hepatocellular carcinoma: A systematic review and network meta-analysis of randomized clinical trials","volume":"11","author":"Liu W","year":"2021","unstructured":"Liu W, Quan B, Lu S, et al. First-line systemic treatment strategies for unresectable hepatocellular carcinoma: A systematic review and network meta-analysis of randomized clinical trials. Front Oncol. 2021;11(December).","journal-title":"Front Oncol"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30436-8"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.05.537"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2020.09.019"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00066-013-0450-y"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2019.02.047"},{"issue":"50","key":"e_1_3_2_22_2","article-title":"Dosimetric comparison among cyberknife, helical tomotherapy and VMAT for hypofractionated treatment in localized prostate cancer","volume":"99","author":"Serra M","unstructured":"Serra M, Ametrano G, Borzillo V, et al. Dosimetric comparison among cyberknife, helical tomotherapy and VMAT for hypofractionated treatment in localized prostate cancer. Med (United States). 2020 Dec 11 [cited 2025 Jun 11];99(50):E23574. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/33327317\/.","journal-title":"Med (United States)"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16193276"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00513-2"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.1.8"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30718-1"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1177\/17588359221134065"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2021.12.001"},{"key":"e_1_3_2_29_2","unstructured":"National Comprehensive Cancer Network. 2025. Kidney Cancer (Version 3.2025) [Internet]. Available from: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1440."},{"key":"e_1_3_2_30_2","unstructured":"Ljungberg B Chair-elect AB Albiges L et al. Renal Cell Carcinoma - EAU Guidelines 2024. 2024."},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-023-01161-5"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2022.01.001"},{"key":"e_1_3_2_33_2","article-title":"Metastasis-directed therapy in the management of urothelial carcinoma: A systematic review and meta-analysis","author":"Miszczyk M","unstructured":"Miszczyk M, Bilski M, K\u00f3i T, et al. Metastasis-directed therapy in the management of urothelial carcinoma: A systematic review and meta-analysis. Eur Urol Focus. 2025 [cited 2025 Jun 14]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/40175243\/.","journal-title":"Eur Urol Focus"},{"key":"e_1_3_2_34_2","doi-asserted-by":"crossref","unstructured":"Tang C Msaouel P Hara K et al. Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma\u202f: a single-arm single-centre feasibility phase 2 trial. 2021;22(December).","DOI":"10.1016\/S1470-2045(21)00528-3"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol30120749"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-022-02793-z"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2011.02.040"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-022-04352-z"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1111\/bju.15541"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13014-021-01937-9"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1111\/bju.15284"},{"issue":"1","key":"e_1_3_2_42_2","first-page":"58","article-title":"Survival outcomes after adding stereotactic body radiotherapy to metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors","volume":"43","author":"He L","year":"2020","unstructured":"He L, Liu Y, Han H, et al. Survival outcomes after adding stereotactic body radiotherapy to metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors. Am J Clin Oncol Cancer Clin Trials. 2020;43(1):58-63.","journal-title":"Am J Clin Oncol Cancer Clin Trials"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2019-000535"},{"key":"e_1_3_2_44_2","doi-asserted-by":"crossref","unstructured":"Zaorsky NG Lehrer EJ Kothari G Louie AV Siva S. Stereotactic ablative radiation therapy for oligometastatic renal cell carcinoma (SABR ORCA): A meta-analysis of 28 studies. 2019;2:524-525.","DOI":"10.1016\/j.euo.2019.05.007"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15133455"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1259\/0007-1285-26-305-234"},{"key":"e_1_3_2_47_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fonc.2012.00191","article-title":"Radiation-induced effects and the immune system in cancer","volume":"2","author":"Kaur P","year":"2012","unstructured":"Kaur P, Asea A. Radiation-induced effects and the immune system in cancer. Front Oncol. 2012;2(December):1-10.","journal-title":"Front Oncol"},{"issue":"8","key":"e_1_3_2_48_2","first-page":"1990","article-title":"Radiation abscopal antitumor effect is mediated through p53","volume":"63","author":"Camphausen K","year":"2003","unstructured":"Camphausen K, Moses MA, M\u00e9nard C, et al. Radiation abscopal antitumor effect is mediated through p53. Cancer Res. 2003;63(8):1990-1993.","journal-title":"Cancer Res"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.2132"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.6_suppl.614"},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1712126"},{"key":"e_1_3_2_52_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-021-03742-1"},{"key":"e_1_3_2_53_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10585-021-10131-w"},{"key":"e_1_3_2_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2019.07.023"},{"key":"e_1_3_2_55_2","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.14730"},{"key":"e_1_3_2_56_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2021.07.026"},{"key":"e_1_3_2_57_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-021-02574-0"},{"key":"e_1_3_2_58_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2022.06.008"},{"key":"e_1_3_2_59_2","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol29100619"},{"key":"e_1_3_2_60_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2021.12.006"},{"key":"e_1_3_2_61_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00066-022-02026-w"},{"key":"e_1_3_2_62_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16172963"},{"key":"e_1_3_2_63_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2021.08.011"},{"key":"e_1_3_2_64_2","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.4133"},{"key":"e_1_3_2_65_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30537-4"},{"key":"e_1_3_2_66_2","first-page":"1","article-title":"Treatment Outcome of metastatic lesions from renal cell carcinoma underGoing Extra-cranial stereotactic body radioTHERapy: The together retrospective study","volume":"22","author":"Buti S","year":"2020","unstructured":"Buti S, Bersanelli M, Viansone A, et al. Treatment Outcome of metastatic lesions from renal cell carcinoma underGoing Extra-cranial stereotactic body radioTHERapy: The together retrospective study. Cancer Treat Res Commun. 2020;22:1-7.","journal-title":"Cancer Treat Res Commun"},{"key":"e_1_3_2_67_2","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pkab050"},{"key":"e_1_3_2_68_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2022.10.004"},{"key":"e_1_3_2_69_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15010313"},{"key":"e_1_3_2_70_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13014-020-01678-1"},{"key":"e_1_3_2_71_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00752-5"},{"key":"e_1_3_2_72_2","doi-asserted-by":"publisher","DOI":"10.3109\/02841851003724846"},{"key":"e_1_3_2_73_2","doi-asserted-by":"publisher","DOI":"10.3892\/mco.2023.2629"},{"key":"e_1_3_2_74_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11547-024-01851-6"},{"key":"e_1_3_2_75_2","doi-asserted-by":"publisher","DOI":"10.1080\/0284186X.2020.1750696"},{"key":"e_1_3_2_76_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-020-06703-1"},{"issue":"42","key":"e_1_3_2_77_2","article-title":"MRI Versus CT for the detection of pulmonary nodules: A meta-analysis","volume":"100","author":"Liu H","unstructured":"Liu H, Chen R, Tong C, Liang XW, Covali R. MRI Versus CT for the detection of pulmonary nodules: A meta-analysis. Med (United States). 2021 Oct 22 [cited 2025 May 11];100(42):E27270. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/34678861\/.","journal-title":"Med (United States)"},{"key":"e_1_3_2_78_2","volume-title":"MRI versus CT in Detecting Pulmonary Nodules. Vol. 304","author":"Perera Molligoda Arachchige AS","year":"2022","unstructured":"Perera Molligoda Arachchige AS. MRI versus CT in Detecting Pulmonary Nodules. Vol. 304. Radiology. Radiological Society of North America Inc.; 2022, p. E51\u20132."},{"key":"e_1_3_2_79_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pathol.2016.05.011"},{"key":"e_1_3_2_80_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-016-0231-6"},{"key":"e_1_3_2_81_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12149-019-01371-8"},{"key":"e_1_3_2_82_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.euros.2022.08.001"},{"key":"e_1_3_2_83_2","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.267417"},{"key":"e_1_3_2_84_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2023.111218"},{"key":"e_1_3_2_85_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12149-024-01904-w"},{"key":"e_1_3_2_86_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11307-018-1271-2"},{"key":"e_1_3_2_87_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15020354"},{"key":"e_1_3_2_88_2","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.268639"},{"key":"e_1_3_2_89_2","first-page":"100608","article-title":"Feasibility of biology-guided radiotherapy for metastatic renal cell carcinoma driven by PSMA PET imaging","volume":"40","author":"Gaudreault M","year":"2023","unstructured":"Gaudreault M, Chang D, Hardcastle N, et al. Feasibility of biology-guided radiotherapy for metastatic renal cell carcinoma driven by PSMA PET imaging. Clin Transl Radiat Oncol. 2023;40(February):100608. https:\/\/doi.org\/10.1016\/j.ctro.2023.100608","journal-title":"Clin Transl Radiat Oncol"},{"key":"e_1_3_2_90_2","first-page":"1354","article-title":"Evaluation of the safety, biodistribution, dosimetry of [18F]AlF-NYM005 and initial experience in clear cell renal cell carcinoma: An interim analysis of a prospective trial","author":"Yang L","year":"2024","unstructured":"Yang L, Guo W, Ding H, et al. Evaluation of the safety, biodistribution, dosimetry of [18F]AlF-NYM005 and initial experience in clear cell renal cell carcinoma: An interim analysis of a prospective trial. Eur J Nucl Med Mol Imaging. 2024:1354-1369.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"e_1_3_2_91_2","doi-asserted-by":"publisher","DOI":"10.7150\/thno.58682"},{"key":"e_1_3_2_92_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22147755"},{"key":"e_1_3_2_93_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16030581"},{"key":"e_1_3_2_94_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.meddos.2023.06.003"},{"issue":"0","key":"e_1_3_2_95_2","article-title":"The role of radiation therapy and particle therapy in renal cell carcinoma: Current evidence and future perspectives","volume":"7","author":"Berghen C","unstructured":"Berghen C, Albersen M, De Roover R, et al. The role of radiation therapy and particle therapy in renal cell carcinoma: Current evidence and future perspectives. J Cancer Metastasis Treat 2021;758. 2021 Oct 20 [cited 2025 Jun 14];7(0):N\/A-N\/A. Available from: https:\/\/www.oaepublish.com\/articles\/2394-4722.2021.123.","journal-title":"J Cancer Metastasis Treat 2021;758"},{"key":"e_1_3_2_96_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.03.043"}],"container-title":["Technology in Cancer Research &amp; Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/15330338251357344","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/15330338251357344","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/15330338251357344","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T06:16:48Z","timestamp":1777702608000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/15330338251357344"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":95,"alternative-id":["10.1177\/15330338251357344"],"URL":"https:\/\/doi.org\/10.1177\/15330338251357344","relation":{"has-review":[{"id-type":"doi","id":"10.1177\/15330338251357344\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/15330338251357344\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/15330338251357344\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/15330338251357344\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/15330338251357344\/v2\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/15330338251357344\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/15330338251357344\/v1\/review2","asserted-by":"object"}]},"ISSN":["1533-0346","1533-0338"],"issn-type":[{"value":"1533-0346","type":"print"},{"value":"1533-0338","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6]]},"article-number":"15330338251357344"}}